Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer.

Yuji Ikeda,Yoshihiro Kikuchi,Masashi Takano,Tomoko Goto,Hiroko Kouta,Naoki Sasaki,Kazuya Kudoh,Katsutoshi Oda,Tsuneki Nagasaka,Tsunekazu Kita

Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer.

2017

Yuji Ikeda
Yoshihiro Kikuchi
Masashi Takano
Tomoko Goto
Hiroko Kouta
Naoki Sasaki
Kazuya Kudoh
Katsutoshi Oda
Tsuneki Nagasaka
Tsunekazu Kita

5037 Background: The combination therapy of gemcitabine with oxaliplatin (GEMOX) has high activity in patients with ovarian cancer. Bevacizumab (B), a vascular endothelial growth factor specific an...

Keywords:

Bevacizumab/Gemcitabine
Pathology
Combination therapy
Vascular endothelial growth factor
Bevacizumab
Oxaliplatin
GemOx
Gemcitabine
Ovarian cancer
Oncology
Medicine
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations